{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:14:19Z","timestamp":1793423659016,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.annonc.2024.08.2243","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T08:50:02Z","timestamp":1726476602000},"page":"1116-1125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7262","authenticated-orcid":false,"given":"S.","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-J.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3147-7640","authenticated-orcid":false,"given":"T.","family":"Reungwetwattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-8628","authenticated-orcid":false,"given":"M.","family":"\u00d6zg\u00fcro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.-H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8698-0590","authenticated-orcid":false,"given":"T.","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.-V.","family":"Quang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-5026","authenticated-orcid":false,"given":"V.","family":"Sriuranpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Armenteros Monterroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Rukazenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8688-8180","authenticated-orcid":false,"given":"T.","family":"van der Gronde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2024.08.2243_bib1","article-title":"Real-world response and outcomes in patients with NSCLC with EGFR exon 20 insertion mutations","volume":"4","author":"Ou","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.annonc.2024.08.2243_bib2","doi-asserted-by":"crossref","first-page":"56998","DOI":"10.18632\/oncotarget.10933","article-title":"A\u00a0retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?","volume":"7","author":"Han","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2024.08.2243_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.912505","article-title":"Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2024.08.2243_bib4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3390\/cancers15030844","article-title":"Advances in the management of central nervous system metastases in non-small cell lung cancer","volume":"15","author":"D\u2019Aiello","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2024.08.2243_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","article-title":"The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer","volume":"45","author":"Peters","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annonc.2024.08.2243_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11523-022-00941-7","article-title":"Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies","volume":"18","author":"Popat","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.annonc.2024.08.2243_bib7","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1002\/cam4.3306","article-title":"Real-world outcomes of chemoradiotherapy for unresectable stage III non-small cell lung cancer: the SOLUTION study","volume":"9","author":"Horinouchi","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.annonc.2024.08.2243_bib8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3892\/ol.2017.6231","article-title":"Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status","volume":"14","author":"Ishihara","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.annonc.2024.08.2243_bib9","first-page":"498","author":"Kim","year":"2023"},{"key":"10.1016\/j.annonc.2024.08.2243_bib10","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1016\/j.cllc.2019.02.021","article-title":"Impact of EGFR mutation and ALK translocation on recurrence pattern after definitive chemoradiotherapy for inoperable stage III non-squamous non-small-cell lung cancer","volume":"20","author":"Nakamura","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.annonc.2024.08.2243_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/jrr\/rrw075","article-title":"The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non\u2013small cell lung cancer: a literature review and pooled analysis","volume":"57","author":"Ochiai","year":"2016","journal-title":"J\u00a0Radiat Res"},{"key":"10.1016\/j.annonc.2024.08.2243_bib12","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1097\/JTO.0000000000000675","article-title":"EGFR mutation impact on definitive concurrent chemoradiation therapy for inoperable stage III adenocarcinoma","volume":"10","author":"Tanaka","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2024.08.2243_bib13","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.08.2243_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.08.2243_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.08.2243_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.08.2243_bib17","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.08.2243_bib18","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.08.2243_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.08.2243_bib20","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.08.2243_bib21","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non\u2013small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.08.2243_bib22","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.08.2243_bib23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis","volume":"15","author":"Ahn","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2024.08.2243_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in\u00a0stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.08.2243_bib25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cllc.2020.11.004","article-title":"Osimertinib maintenance after definitive chemoradiation in patients with unresectable EGFR mutation positive stage III non-small-cell lung cancer: LAURA trial in progress","volume":"22","author":"Lu","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.annonc.2024.08.2243_bib26","series-title":"IASLC Staging Handbook in Thoracic Oncology","author":"Rami-Porta","year":"2016"},{"key":"10.1016\/j.annonc.2024.08.2243_bib27","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/ijc.IJC_455_19","article-title":"Management of CNS metastases in patients with EGFR mutation-positive NSCLC","volume":"56","author":"Vijith","year":"2019","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.annonc.2024.08.2243_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4143\/crt.2018.125","article-title":"EGFR mutation is associated with short progression-free survival in patients with stage III non-squamous cell lung cancer treated with concurrent chemoradiotherapy","volume":"51","author":"Park","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.annonc.2024.08.2243_bib29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/14737140.2019.1621754","article-title":"The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis","volume":"19","author":"Qin","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.annonc.2024.08.2243_bib30","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer Version 7. 2024. Accessed July 22,\u00a02024."},{"key":"10.1016\/j.annonc.2024.08.2243_bib31","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO-24-01324","article-title":"Management of stage III non-small cell lung cancer: ASCO rapid recommendation update","volume":"42","author":"Daly","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.08.2243_bib32","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.08.2243_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.08.2243_bib34","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/cts.13500","article-title":"Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: a positron emission tomography and magnetic resonance imaging study","volume":"16","author":"Ekman","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.annonc.2024.08.2243_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/0271678X19843776","article-title":"A\u00a0PET study in healthy subjects of brain exposure of (11)C-labelled osimertinib\u2014a drug intended for treatment of brain metastases in non-small cell lung cancer","volume":"40","author":"Varrone","year":"2020","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.annonc.2024.08.2243_bib36","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer","volume":"42","author":"J\u00e4nne","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.08.2243_bib37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/annonc\/mdx820","article-title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","volume":"29","author":"Goss","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424038237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424038237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T15:38:55Z","timestamp":1734709135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424038237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0923753424038237"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2243","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}